Drugs / WNT974
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01351103 | Dec 2011 → Jun 2021 | cervical squamous cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, malignant pancreatic neoplasm +3 | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02278133 | Dec 2014 → May 2016 | colorectal cancer | Array BioPharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02649530 | ? → Jul 2018 | head and neck squamous cell carcinoma | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WNT974 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02278133 ↗ |
| Known as | LGK974 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01351103 ↗ |
| Action | Inhibit | “WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase.” PMID 36811382 ↗ Mar 2023 |
| Modality | Small molecule | “WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase.” PMID 36811382 ↗ Mar 2023 |
| Route | Oral | “Oral LGK974” NCT01351103 ↗ |
| Target | PORCN | “WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase.” PMID 36811382 ↗ Mar 2023 |